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Abstract
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Objective.—Fatigue is consistently ranked as one of the most problematic symptoms in systemic
sclerosis (SSc), but the impact of fatigue on daily life is not well-characterized. The purpose of
this study was to examine fatigue’s contribution to deficits in social participation, functioning, and
quality of life.
Methods.—Baseline data from a sample undertaking a clinical trial were utilized (N = 267).
Fatigue, pain interference, depressive symptoms, physical function, and social participation were
assessed by PROMIS measures. Hierarchical linear regressions were performed to determine
fatigue’s unique contribution to social participation, physical function, and quality of life, above
and beyond the effects of demographic and clinical variables, pain interference, and depressive
symptoms.
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Results.—The sample was predominantly female (91%), with average age 53.7 years, average
disease duration of 9 years, and mean fatigue T-score of 58.7. Of all outcomes, fatigue was most
strongly associated with deficits in social participation, explaining 48% of the variance beyond
demographic and clinical factors, which is similar to the amount of variance contributed by pain
interference and depressive symptoms combined (49%). Fatigue also accounted for significant
amounts of variance in physical function and quality of life (R2 = .27 and .33 respectively) above
and beyond the effects of demographic and clinical factors.
Conclusion.—Fatigue is an important clinical problem in SSc and is strongly associated with
decreased participation in social roles and activities. Rehabilitation interventions that focus on
fatigue management may be necessary to maximize participation.
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Systemic sclerosis (SSc) is a rare autoimmune disease associated with vascular damage and
tissue fibrosis that affects the skin and internal organs (1–3). In the US, it affects between
13.5 – 39.9 per 100,000 people (4). In addition to the classic skin hardening that restricts
movement, a major complaint of people with SSc is the substantial symptom burden.
Symptoms such as fatigue, pain, and depressive symptoms are common, and because SSc is
diagnosed in early to middle age and has no cure, individuals with SSc face many years of
managing the manifestations of a complex and progressive condition (5).
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Symptoms in SSc significantly disrupt daily activities and diminish quality of life (6–9). Of
the symptoms experienced, fatigue has been consistently ranked as one of the most
problematic (6, 7, 10–12). Fatigue in SSc is significantly greater than what is experienced by
the general population, similar to other rheumatological conditions and those who are
actively in cancer treatment (8,9,12). Fatigue affects many facets of life, diminishing the
ability to perform usual tasks (7, 13), engage in meaningful activities (7, 14), perform work
duties (15, 16) and fulfill family responsibilities (14, 17, 18). The debilitating nature of
fatigue has prompted a call for research to better understand fatigue and its correlates (6, 7,
9, 14) in order to better address this symptom to reduce disability and improve quality of
life.
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To better understand the contribution of fatigue to functioning and quality of life in SSc, we
examined baseline data from a sample of participants who undertook a clinical trial
investigating the effectiveness of an internet-based self-management program (19). The
purpose of this study was to examine fatigue’s contribution to deficits in social participation,
functioning, and quality of life in people with SSc. We hypothesized that fatigue would be
the strongest unique contributor to each of these outcomes in multivariable models that
included other symptoms (pain interference and depressive symptoms), clinical variables,
and demographics.

PATIENTS AND METHODS
Procedure.

Author Manuscript

Adults with SSc were recruited to participate in a randomized controlled trial designed to
evaluate the efficacy of an internet-based chronic disease self-management program (19).
People were recruited from two universities (in the Midwest and South Eastern United
States) as well as from websites and social media from national SSc foundations. To be
included in the trial, people needed to be US residents, report a diagnosis of SSc, be 18 years
or older, have basic computer literacy and access to a computer with internet and email
capabilities, be able to communicate in English, and be willing to complete the study
procedures. All participants provided informed consent. After informed consent was
obtained, participants were sent a Qualtrics survey to complete baseline assessments
examined in this secondary data analysis. The study was approved by institutional human
subjects review boards at the University of New Mexico, University of Michigan, and
Medical University of South Carolina.
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Measures
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Fatigue.—Fatigue was measured using the 4 items from the fatigue subscale of the Patient
Reported Outcomes Measurement Information System (PROMIS) 29 version 2.0 (v.2). The
PROMIS 29 v.2 contains several scales used in this analysis which have been validated in a
large international sample of people with SSc (20). Items are referenced for the past 7 days
and rated on a scale from 1 (not at all) to 5 (very much): 1) I feel fatigued; 2) I have trouble
starting things because I am tired; 3) How run-down did you feel on average? and 4) How
fatigued were you on average? Ratings were converted to a T score metric which
standardized the ratings to the US population in which the mean is 50 and standard deviation
is 10. A higher score indicates worse fatigue.
Outcomes
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Social Participation.—The Ability to Participate in Social Roles and Activities scale was
part of the PROMIS 29 and consists of 4 items. On a scale of 5 (Never) to 1 (Always),
participants were asked to rate the following: 1) I have trouble doing all of my regular
leisure activities with others 2) I have trouble doing all of the family activities that I want to
do; 3) I have trouble doing all of my usual work (include work at home) and 4) I have
trouble doing all of the activities with friends that I want to do. Scores were converted to T
scores for analysis. A higher score indicates better ability.
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Physical Function.—The PROMIS 29 v.2 has a physical function scale with 4 items. On
a scale of 5 (without any difficulty) to 1 (unable to do), participants were asked to rate the
following: 1) Are you able to do chores such as vacuuming or yard work? 2) Are you able to
go up and down stairs at a normal pace? 3) Are you able to go for a walk of at least 15
minutes? and 4) Are you able to run errands and shop? A higher score indicates better
physical function.
Quality of Life.—The EuroQol 5-domain instrument (EQ-5D-5L) is a generic healthrelated quality of life assessment commonly used in samples with various chronic conditions
(21, 22). It has domains of mobility, self-care, activity, pain, and anxiety. Participants are
asked to rate their health state on a scale of no problems, slight problems, moderate
problems, severe problems and extreme problems. Responses are then transformed to a
metric of health utility using an algorithm in which scores range from 0.0 (death) to 1.0
(full/optimal health).
Demographic and Clinical Characteristics
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Demographic information included age, race, ethnicity, sex, education level, marital status,
and employment status. Clinical characteristics included scleroderma type (limited/CREST/
sine, diffuse, or overlap), and disease duration (measured as the year diagnosed). Self-rated
health was ascertained through one question in which participants rated their overall health
as excellent, very good, good, fair, or poor.
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Other Symptoms
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Pain interference and Depressive symptoms.—Both of these symptoms were
assessed from the PROMIS scales from the PROMIS 29 v.2. Pain interference was assessed
by 4 items. In the past 7 days, participants rated pain interference on a scale of 1 (not at all)
to 5 (very much) in the following questions: 1) How much did pain interfere with your day
to day activities? 2) How much did pain interfere with work around the home? 3) How much
did pain interfere with your ability to participate in social activities? and 4) How much did
pain interfere with your household chores? Depressive symptoms were also assessed in the
past 7 days. On a scale of 1 (never) to 5 (always), participants rated the following: 1) I felt
worthless; 2) I felt helpless; 3) I felt depressed; and 4) I felt hopeless. Higher scores on these
scales indicated worse symptoms.
Data Analysis

Author Manuscript
Author Manuscript

Descriptive statistics were used to characterize the sample. We used frequency and
proportion for categorical variables, means and standard deviations for normally distributed
continuous data and median and interquartile ranges for non-normally distributed continuous
data. The association between fatigue (T score from the PROMIS measure) and three
outcome variables was investigated in three separate hierarchical multivariable linear
regression analyses with outcome variables: social participation, physical function, and
quality of life. For each outcome, 3 models were constructed to examine the relative
contributions of fatigue and other symptoms (pain interference and depressive symptoms)
above and beyond demographic and clinical variables. This method allowed us to examine
the unique contribution of fatigue and the set of other symptoms respectively to the model
variance without the influence of each other. It also allowed for comparison across models
given the difference in order of entry. In Model 1, demographic and clinical variables (age,
gender, race, scleroderma subtype, and years since scleroderma diagnosis) were entered in
Block 1 and fatigue was entered in Block 2. In Model 2, demographic and clinical variables
were entered in Block 1, fatigue in Block 2, and pain interference and depressive symptoms
in Block 3. Model 2 was performed to examine how much the symptom of fatigue explained
the variance in each outcome above and beyond clinical factors, and how much unique
variance is then explained by pain interference and depressive symptoms. In Model 3 the
order of entry of the pain interference and depressive symptoms block and the fatigue block
were reversed. Model 3 was performed to examine how much unique variance fatigue adds
to the model above and beyond demographic and clinical variables and symptoms of pain
interference and depressive symptoms. R2 values indicated the amount of variance in the
outcomes attributable to the variable blocks entered into the models. To depict the
unadjusted relationship between fatigue and social participation, a scatter plot with overlaid
best-fitting lines was constructed, estimated using ordinary least squares piecewise
regression. We pre-specified a cut-point of 1SD below the sample fatigue T-score mean.

Author Manuscript

RESULTS
The characteristics of the sample have been reported in detail elsewhere (19). In brief, the
sample was predominantly female (91%), the mean age was 53.7 years (SD 11.7), and
consisted of 17% racial/ethnic minorities (non-white). Almost three quarters of the sample
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(74%) had academic degrees or professional qualifications with a mean of 16 years of
education; 64% were married, and 42% reported working part or fulltime. For the
scleroderma subtype reported by participants, 45% had limited cutaneous systemic sclerosis
or sine scleroderma; 43% had diffuse cutaneous systemic sclerosis; 12% had scleroderma
overlapping with another rheumatic disease, and 0.4% (n = 1) did not know the subtype.
Time since diagnosis was a median of 9 years with an interquartile range of 5 – 16.
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Table 1 shows the values for reported functioning, health, and symptom measures. 43.9% of
the sample rated their overall health to be fair or poor. Fatigue was the worst rated symptom
(Mean T = 58.7 or 0.87 SD above the US Population) followed by pain interference (Mean T
= 58.0). Mean anxiety, sleep disturbance, and depressive symptoms were all within .5
standard deviations of the normative sample mean (T = 50). Using one way analyses of
variance or chi-square tests to examine differences across SSc subtype, only fatigue, sleep
disturbance, and self-rated health were significantly different (p ≤ 0.05). Participants with
overlap SSc had the highest levels of fatigue and sleep disturbance, and the highest
proportion of people who rated their health as fair or poor (51.6%). Participants with diffuse
SSc also had a high proportion of people who rated their health as fair or poor (50.5%), but
their mean fatigue and sleep disturbance levels were similar to those with limited or sine
SSc.
Fatigue and Social Participation
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Table 2 shows results from hierarchical regression models where fatigue and other variables
were examined as predictors of social participation. In Model 1, 50% of the variance in
social participation was explained by demographic and clinical factors, which contributed a
negligible amount (2%) of variance and by fatigue, which accounted for nearly half (48%) of
the variance. Of the demographic and clinical factors, age and the diffuse SSc subtype
demonstrated significant independent negative associations with social participation. When
pain interference and depressive symptoms were added in a block after fatigue (Model 2), a
further increase of 11% of variance in the outcome was explained by these symptoms. In the
Model 3, fatigue accounted for a significant amount of variance (9%) above and beyond the
effects of pain interference and depressive symptoms combined (49% of variance).
Regardless of order of entry, the models accounted for approximately 60% of the variance in
social participation.

Author Manuscript

Figure 1 shows the unadjusted association between fatigue and social participation, with the
best-fit line segmented at 1SD below the sample mean (fatigue mean T score 48). In this
graph, the negative association between fatigue and social participation is only seen when
people have fatigue that is approximately at the mean or greater (T-score of 48 or higher).
Fatigue was not associated with social participation for people with low fatigue.
Fatigue and Physical Function—Table 3 shows the results from the hierarchical
regression models where physical function was the outcome. In Model 1, 30% of the
variance in physical function was explained by demographic and clinical factors (3%
combined) and fatigue (27% of the variance). Age and diffuse SSc were significantly
negatively associated with physical function and depressive symptoms. In Model 2, fatigue
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accounted for a significant and substantial amount of variance in physical function (27%);
pain and depressive symptoms added a significant amount of variance above and beyond the
effect of fatigue on physical function. In Model 3, pain interference and depressive
symptoms accounted for a substantial and significant amount of variance in physical
function (37%); fatigue added a statistically significant though small amount of variance in
physical functioning when added in the third step. The models accounted for 43% of the
variance in self-reported physical function.

Author Manuscript

Fatigue and Quality of Life—Table 4 shows the results from the hierarchical regression
models where quality of life was the outcome. In Model 1, 35% of the variance in quality of
life was explained by demographic and clinical factors and fatigue; as in prior models,
demographic and clinical variables accounted for very small amounts of the variance in
quality of life (2%), whereas fatigue accounted for 33% of the variance. Of the demographic
factors, diffuse SSc was significantly associated with lower quality of life. In Model 2, pain
interference and depressive symptoms contributed an additional 21% variance in quality of
life, above and beyond the effects of fatigue. In contrast, in Model 3, fatigue only
contributed an additional 1% variance in quality of life, above the variance explained by pain
interference and depressive symptoms, which accounted for 53% of the variance in quality
of life. These models explained 56% of the variance in quality of life and depressive
symptoms.

DISCUSSION
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Fatigue is a symptom often described in the literature as debilitating by people with SSc (6,
10, 11), but it is not yet clear what aspects of functioning and quality of life are most
affected by fatigue and other symptoms. In this study, our objective was to examine fatigue’s
contribution to deficits in social participation, functioning, and quality of life. To accomplish
this, we examined the relative contributions of fatigue above and beyond demographics and
clinical factors and other symptoms (pain interference and depression).
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We have three main findings from this study. First, of all outcomes assessed, fatigue was
most strongly associated with decreased ability to participate in social roles and activities.
Fatigue alone accounted for nearly the same amount of variance in social participation (R2
= .48 in Table 2 Model 2) as pain interference and depressive symptoms combined (R2 = .49
in Table 2 Model 3). Furthermore, the substantial amount of unique variance that fatigue
explained over and above symptoms of pain interference and depressive symptoms suggest
that fatigue is particularly influential with regard to reduced social participation. These
findings are in contrast to those of Sandusky et al. who reported that fatigue was not a
significant correlate for social participation after controlling for depressive symptoms (7)
and Poole et al. (24) using a single VAS measure for fatigue, who reported no difference in
social participation with higher levels of fatigue. However, there are several key differences
in the measurement of social participation between the current study and those studies.
Sandusky et al. measured social participation via social networks and relationships as
opposed to participation in particular activities, and Poole et al. measured social
participation by ascertaining frequency of performance of activities, such as gardening,
household maintenance, and shopping, and counted higher frequency as better participation.
Arthritis Care Res (Hoboken). Author manuscript; available in PMC 2022 March 01.
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In the current study, social participation was measured using the PROMIS social
participation scale which assesses the perception of difficulty in usual social activities and
factors in the whether participation is above or below what the individual wants to do. In
addition, the PROMIS social participation has been validated and has stronger psychometric
properties compared to the instruments used in the prior studies. Lastly, differences in this
study’s sample and those studies may also affect the comparisons. For instance, in the
Sandusky et al study, a higher proportion of people reported having a high school education
or less (32%) in relation to this sample (20%).
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One reason why fatigue may have a strong negative association to social participation is
because work limitations are included in the social participation measure. In SSc, fatigue is a
strong correlate of work disability (25,26), and baseline fatigue severity was a main
predictor of work disability in a longitudinal study (27). This study’s findings showing a
strong negative association between fatigue and social participation is similar to that of
studies in another chronic condition, multiple sclerosis (28,29). In those studies, pain and
depressive symptoms are also important factors in decreased physical function and quality of
life.
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Our findings have implications for both assessment and intervention development. While
clinical assessment often includes measures of physical function, it appears important to
include measures of social participation when assessing patients with SSc, especially if they
report high fatigue. In addition, the assessment used to measure fatigue is an important
consideration also as some assessments such as the Multidimensional Fatigue Inventory and
Multidimensional Assessment of Fatigue Scale include items asking about the impact of
fatigue on participation. Assessment of social participation may reveal areas for intervention
that would be appropriate for rehabilitation professionals to address, such as workplace
adaptation, and also supports the idea that fatigue management is necessary in this
population, similar to others recommendations (6, 7, 9, 12, 14).
Second, although fatigue accounted for about one third of the variance in physical function
and quality of life outcomes when entered in the models prior to the addition of pain
interference and depressive symptoms, fatigue did not significantly contribute to the
variance in physical function and quality of life after these symptoms were included in the
models (only 1% and 3% respectively). The findings suggest that interventions to impact
physical function and quality of life need to be multifaceted and include strategies to reduce
pain and depressive symptoms in addition to fatigue management. Indeed, other studies have
confirmed this relationship between fatigue, pain, depressive symptoms and function (7, 12,
30).
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Third, this finding extends the understanding of how demographics and clinical factors relate
to symptoms, functioning and quality of life in SSc. Neither age nor disease subtype was
associated with the outcomes measured. Interestingly, people with SSc all have relatively
high symptom severity compared to normative samples and people with the two main
subtypes of SSc (diffuse and limited) have somewhat similar fatigue levels (T = 57 and 58).
This is similar to a previous study that showed no significant differences in fatigue by
subtype (7). Although fatigue severity was similar in these groups, people with diffuse SSc
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have greater deficits in their ability to participate in social roles and activities suggesting that
fatigue management is particularly important in this group. Moreover, lung, gastrointestinal
and muscle involvement, more common with diffuse SSc, have been reported to be
predictors of fatigue (12).

Limitations
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This study utilized cross-sectional data so causality between fatigue and outcomes cannot be
assumed. Further, participants were a national sample who self-reported all measures via
survey so clinical variables could not be corroborated by medical records. In addition, other
measures of health status such as number and types of comorbidities were not collected and
this information could have further explained variance in the functioning and quality of life
outcomes. Future studies should examine longitudinal associations between fatigue and
social participation.

Conclusion
This study showed that fatigue related strongly to deficits in the ability to participate in
social roles and activities. Intervention development for fatigue management may be
particularly needed to maximize social participation in this population.
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SIGNIFICANCE AND INNOVATIONS
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•

Fatigue is associated with physical function, quality of life, and social
participation. People with SSc and higher levels of fatigue had reduced ability
to participate in social roles and activities.

•

Fatigue explains the same amount of variance in social participation as pain
and depressive symptoms combined. After pain and depressive symptoms are
in the model, fatigue explains an additional 9% of variance in social
participation.

•

Fatigue was a significant predictor of physical function and quality of life,
though pain interference and depressive symptoms accounted for more
variability, suggesting that different symptoms have variable effects
depending on the functional domain.
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Figure 1. Unadjusted Relationship between Fatigue and Social Participation

Note. Social participation is measured by the PROMIS Ability to Participate in Social Roles
and Activities. Both axes depict T scores. The cut-point used (depicted by the dotted line
above) is 1 SD below the sample mean for PROMIS Fatigue (T = 48).
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Table 1.

Author Manuscript

Sample Reported Symptoms, Functioning, and Quality of Life (N = 267)

Author Manuscript

Measures

Overall Sample

Diffuse SSc
N=115

Limited SSc
N=120

Overlap SSc
N=31

Fatigue*

58.7 (10.4)

57.5 (10.1)

58.4 (10.4)

63.7 (10.1)

Pain interference

58.0 (9.3)

56.9 (9.7)

58.0 (8.8)

61.4 (8.9)

Pain intensity (0–10 NRS)

4.2 (2.2)

3.9 (2.3)

4.2 (2.1)

4.9 (2.2)

Depressive symptoms

51.3 (9.8)

51.3 (10.1)

51.3 (10.0)

51.6 (8.7)

Anxiety

54.0 (10.0)

53.4 (9.9)

54.4 (10.1)

54.7 (10.5)

Sleep disturbance *

53.7 (6.5)

53.9 (6.5)

52.5 (5.7)

57.0 (8.2)

Social Participation

45.0 (8.2)

44.9 (8.0)

45.8 (8.5)

43.3 (7.2)

Quality of Life EQ-5D-5L

0.78 (0.08)

0.78 (0.08)

0.79 (0.08)

0.77 (0.07)

Excellent

3 (1.1%)

3 (2.6%)

0 (0%)

0 (0%)

Very good

33 (12.4%)

16 (13.9%)

15 (12.5%)

1 (3.2%)

Good

114 (42.7%)

38 (33.0%)

62 (51.7%)

14 (45.2%)

Fair

100 (37.5%)

51 (44.4%)

36 (30.0%)

13 (41.9%)

Poor

17 (6.4%)

7 (6.1%)

7 (5.8%)

3 (9.7%)

Self-rated health (n, %)*

Note. The PROMIS 29 v.2 was used which comprised scales of Fatigue, Pain Interference, Pain Intensity, Depressive symptoms, Anxiety, Sleep
Disturbance, Ability to Participate in Social Roles (Social Participation), and Physical Function. Unless otherwise noted, statistics represented in
the table show the mean (standard deviation) for each variable.

*

p ≤ 0.05 difference among SSc subtypes
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Table 2.

Author Manuscript

The Association of Fatigue with Ability to Participate in Social Roles
Model 1
Block

B

Model 2
ΔR2

Block

82.83*

Constant
Demographics/ Clinical Factors

1

B

Model 3
ΔR2

Block

94.93*
.02

1

B
94.93*

.02

1

.02

−0.10*

−0.12*

−0.12*

Female

1.62

1.51

1.51

Minority

1.03

1.51

1.51

†

−1.49*

−1.65*

−1.65*

†

0.10

−0.19

−0.19

Age

Diffuse SSc

Overlap SSc

Author Manuscript

Diagnosis year

−0.04

Fatigue

2

−0.56*

−0.03
.48*

Pain interference

.50

Total Model R2

−0.03

2

−0.32*

.48*

3

−0.28*

.09*

3

−0.28*

.11*

2

−0.16*

.49*

−0.16*

Depressive symptoms

ΔR2

0.32*
.61

.60

Note. Fatigue, Ability to Participate in Social Roles and Activities, Pain Interference, and Depressive symptoms are scales taken from the PROMIS
29 v.2. Hierarchical regression models were constructed with variable(s) entered in blocks. Beta coefficients included in the table are from full
models; ΔR2 is shown for Pain Interference and Depressive symptoms in combination as they were entered together in a block. N=266 in all
models (1 participant had missing data for SSc type).

†

Reference group: Limited or sine scleroderma

*

p ≤ .05
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Table 3.

Author Manuscript

The Association of Fatigue with Physical Function
Model 1
Block

B

Model 2
ΔR2

Block

66.41*

Constant
Demographics/ Clinical Factors

1

B

Model 3
ΔR2

Block

76.51*
.03

1

B
76.51*

.03

1

.03

−0.07*

−0.09*

−0.09*

Female

0.84

1.13

1.13

Minority

0.47

1.00

1.00

†

−1.84*

−2.05*

−2.05*

†

−1.23

−1.15

−1.15

Age

Diffuse SSc

Overlap SSc

Author Manuscript

Diagnosis year

−0.07

Fatigue

2

−0.36*

−0.06
.27*

Pain interference
Depressive symptoms

−0.06

2

−0.16*

.27*

3

−0.16*

.03*

3

−0.35*

.13*

2

−0.35*

.37*

−0.03
.30

Total Model R2

ΔR2

−0.03
.43

.43

Note. Fatigue, Physical Function, Pain Interference, and Depressive symptoms are scales taken from the PROMIS 29 v.2. Hierarchical regression
models were constructed with variable(s) entered in blocks. Beta coefficients included in the table are from full models; ΔR2 is shown for Pain
Interference and Depressive symptoms in combination as they were entered together in a block. N=266 in all models (1 participant had missing
data for SSc type).

†

Reference group: Limited or sine scleroderma

*

p ≤ .05
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Table 4.

Author Manuscript

The Association of Fatigue with Quality of Life
Model 1
Block

B

Model 2
ΔR2

Block

1.05*

Constant
Demographics/ Clinical Factors

1

Age

ΔR2

Block

1.22*
.02

1

−0.0001

Female

B

Model 3
B
1.22*
.02

1

−0.0004

.02
−0.0004

0.02

0.02

0.02

−0.004

0.002

0.002

†

−0.01

−0.02*

−0.02*

†

−0.004

−0.008

−0.008

−0.0004

−0.0003

−0.0003

Minority
Diffuse SSc

Overlap SSc

Diagnosis year

Author Manuscript

Fatigue

2

−0.005*

.33*

Pain interference

.35

Total Model R2

2

−0.001*

.33*

3

−0.001*

.01*

3

−0.004*

.21*

2

−0.004*

.53*

−0.002*

Depressive symptoms

ΔR2

−0.002*
.56

.56

Note. Quality of Life was measured using the EuroQol 5D-5L instrument. Fatigue, Pain Interference, and Depressive symptoms are scales taken
from the PROMIS 29 v.2. Hierarchical regression models were constructed with variable(s) entered in blocks. Beta coefficients included in the
table are from full models; ΔR2 is shown for Pain Interference and Depressive symptoms in combination as they were entered together in a block.
N=266 in all models (1 participant had missing data for SSc type).

†

Reference group: Limited or sine scleroderma

*

p ≤ .05
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